CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
-7.2%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$448M
AUM Growth
+$448M
(+3.7%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
14.19%
Top 10 Holdings %
Top 10 Hldgs %
71.5%
Holding
29
New
4
Increased
9
Reduced
3
Closed
2
Top Buys
| 1 |
Karyopharm Therapeutics
KPTI
|
$26.2M |
| 2 |
BLU
BELLUS Health Inc.
BLU
|
$17.3M |
| 3 |
Kura Oncology
KURA
|
$12.5M |
| 4 |
Immunic
IMUX
|
$10.1M |
| 5 |
Cogent Biosciences
COGT
|
$9.13M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$16.9M |
| 2 |
Protagonist Therapeutics
PTGX
|
$11.2M |
| 3 |
ALLK
Allakos
ALLK
|
$7.99M |
| 4 |
Aclaris Therapeutics
ACRS
|
$6.17M |
| 5 |
KRON
Kronos Bio
KRON
|
$4.06M |
Sector Composition
| 1 | Healthcare | 99.45% |
| 2 | Financials | 0.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $48M | 10.73% | 1,816,421 +317,531 | +21% | +$8.4M |
|
|
2
Aclaris Therapeutics
ACRS
$209M
| $39.9M | 8.91% | 2,314,648 -357,698 | -13% | -$6.17M |
|
|
BLU
3
DELISTED
BELLUS Health Inc.
BLU
| $38.8M | 8.66% | 5,637,630 +2,513,017 | +80% | +$17.3M |
|
|
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $37.3M | 8.33% | 2,214,961 -1,002,202 | -31% | -$16.9M |
|
5
Xenon Pharmaceuticals
XENE
$2.98B
| $36.8M | 8.21% | 1,202,613 +112,487 | +10% | +$3.44M |
|
6
Cytokinetics
CYTK
$4.23B
| $31.5M | 7.03% | 854,652 +150,115 | +21% | +$5.53M |
|
|
7
Karyopharm Therapeutics
KPTI
$61.7M
| $26.2M | 5.86% | +3,561,052 | New | +$26.2M |
|
|
8
Cogent Biosciences
COGT
$1.69B
| $26.2M | 5.86% | 3,500,768 +1,219,453 | +53% | +$9.13M |
|
|
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
| $17.8M | 3.99% | 5,738,500 +318,604 | +6% | +$991K |
|
10
Viridian Therapeutics
VRDN
$1.5B
| $17.6M | 3.93% | 951,339 +103,656 | +12% | +$1.92M |
|
|
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
| $14.3M | 3.2% | 1,744,570 +497,527 | +40% | +$4.09M |
|
|
STSA
12
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $14.1M | 3.15% | 3,711,286 | – | – |
|
13
VistaGen Therapeutics
VTGN
$102M
| $12.5M | 2.8% | 10,097,229 +1,632,230 | +19% | +$2.02M |
|
|
14
Kura Oncology
KURA
$686M
| $12.5M | 2.79% | +776,514 | New | +$12.5M |
|
15
C4 Therapeutics
CCCC
$185M
| $11.7M | 2.61% | 481,094 | – | – |
|
|
16
Immunic
IMUX
$80.9M
| $10.1M | 2.25% | +893,013 | New | +$10.1M |
|
17
Celcuity
CELC
$2.17B
| $8.61M | 1.92% | 920,464 | – | – |
|
18
Celldex Therapeutics
CLDX
$1.47B
| $8.22M | 1.83% | +241,199 | New | +$8.22M |
|
|
19
Protagonist Therapeutics
PTGX
$3.67B
| $7.86M | 1.76% | 331,886 -473,687 | -59% | -$11.2M |
|
20
Tenaya Therapeutics
TNYA
$184M
| $6.05M | 1.35% | 513,930 | – | – |
|
21
KalVista Pharmaceuticals
KALV
$678M
| $4.61M | 1.03% | 312,553 | – | – |
|
|
GNCA
22
DELISTED
Genocea Biosciences, Inc.
GNCA
| $3.85M | 0.86% | 3,079,756 | – | – |
|
|
IVA
23
Inventiva
IVA
$861M
| $2.99M | 0.67% | 262,658 | – | – |
|
24
Dyne Therapeutics
DYN
$1.92B
| $2.94M | 0.66% | 305,125 | – | – |
|
25
PMV Pharmaceuticals
PMVP
$74.2M
| $2.6M | 0.58% | 125,000 | – | – |
|